Innovation Days 2013
partnering RESEARCH and business |
BECKURTS AWARDS
Germany’s leading research organisations present their assets
9 and 10 December 2013
Partnering ConferEnce at dbb forum berlin
9 december 2013
Beckurts Awards & Evening Reception at Rotes Rathaus
RESEARCH MEETS BUSINESS PARTNERING FORUM 2013
in the fields of Life Sciences (Focus on Medical Technologies) and
Information and Communication Technologies (Focus on Big Data)
Organized by
Co-organized by
WORDS OF WELCOME
On behalf of the Helmholtz Association and our co-organisers, the Max Planck Society, the Fraunhofer-Gesellschaft
and the Leibniz Association, it is a great pleasure to welcome you to Berlin for the second edition of the Innovation Days. Following the successful premiere of the event
in 2012, this partnering platform between research and
business will once again provide an exclusive opportunity
to learn more about application-related technologies and high-performance
spin-off projects by the leading German research organisations and to meet
innovative researchers, technology transfer experts and decision-makers
from industry and financial investment in an effective set-up.
By establishing this event, Germany’s four leading research organisations are demonstrating their commitment to their mission and obligation
under the Joint Initiative for Research and Innovation: the creation of ideal
conditions for translating research findings into benefits for business and
society is one of the main goals of this initiative. We would like to thank our
co-host Bayer AG and all our partners and sponsors from society, research
and business for sharing this approach and supporting the continuation of
the Innovation Days.
We hope that the Innovation Days 2013 will be as inspiring and openminded as the premiere last year. We would like to encourage you to take
full advantage of this partnering opportunity and to be part of a productive
exchange between academic research and business.
2
Prof. Dr Jürgen Mlynek,
Dr Rolf Zettl,
President
Helmholtz Association
Managing Director
Helmholtz Association
3
Innovation Days 2013:
partnering RESEARCH and business | BECKURTS AWARDS
9 December 2013 – dbb forum berlin & ROTES RATHAUS
TIME
11.00–11.15
TIME
Atrium I + II
Chairman: Dr Jörn Erselius (Max Planck Innovation GmbH)
Success factors in the strategic partnership between Bayer
and DKFZ
13.30 –15.00 Opening Plenary Session
Welcome and Introduction
Partnering
Prescheduled
One-to-OneMeetings
(30 min)
Fraunhofer Industry Collaborations: How does it work?
Impulse Talk on Innovation by Partnering and Cooperation
Prof. Dr Ralf Dudde (ISIT)
Prof. Dr Wolfgang Plischke (Bayer AG)
Lead Discovery Center (LDC): A New Model for Pharma Innovation
Key Note on Research and Innovation in Medical Technologies / Imaging
From scanning tunneling microscope to Tissue Phenomics and Big Data
Dr Bert Klebl (LDC) and Julie Wallis (Merck Serono)
Financing Innovation:
From Spinnovator to HTGF and Venture Capital
Prof. Dr Gerd Binnig (Definiens AG)
Key Note on Research and Innovation in ICT / Big Data
How to be a Game Changer: Innovations in Audio
Dr Katja Rosenkranz (Spinnovator / Ascenion GmbH), Matthias Dill (HTGF)
and Ute Mercker (ibb bet)
Prof. Dr Karlheinz Brandenburg (IDMT)
Discussion
15.00 –15.15 Coffee Break
13.00 –14.00 Lunch
Atrium I + II
Atrium IV + V
14.00 –15.45 SESSION II: Using Unique Infrastructure
Pitching Technologies
Life Sciences (Focus on MedTech)
Pitching Spin-Offs
ICT (Focus on Big Data)
Moderation: Christine Wennrich / Erik Schulz (Leibniz Association)
Moderation: Matthias Keckl / Sebastian Surma (Fraunhofer Venture)
TIME
17.45–19.15
dbb forum
Partnering
Booths
Dr Ruth Wellenreuther (DKFZ) and Dr Holger Hess-Stumpp (Bayer AG)
Dr Rolf Zettl (Helmholtz Association), Chairman of the Session
15.15–17.00
Coffee break
11.15 –13.00 SESSION I: Models, Deals and Instruments
13.00 –13.30 Registration & Coffee
TIME
Atrium I + II
Chairman: Prof. Dr Andreas Schreyer (HZG)
Introduction and Overview of large-scale research facilities with a
focus on PETRA III, XFEL, BERII, BESSY II, ANKA, Ion Beam Center
Prof. Dr Kaysser-Pyzalla (HZB)
How can industry take advantage of large-scale research facilities?
The case of drug discovery
Berlin City Hall (Rotes Rathaus)
Beckurts Awards Ceremony (in German)
Dr Martina Schäfer (Bayer AG)
Key Note by Prof. Dr Harald zur Hausen (DKFZ)
Material Testing and Research with Synchrotrons and Neutrons
(Please see Invitation of Beckurts-Stiftung for detailed program)
Dr Thomas Gutberlet (HZB) and Dr Hermann Franz (DESY)
Leibniz Application Labs
19.15–22.00 Evening Reception
Dr Silvia Adelhelm (AIP)
Fraunhofer Application Center for Plasma and Photonics
Dr Bernd Schieche (IST)
Medical Innovation Lab
10 December 2013 – dbb forum berlin
TIME
8.30 –9.00
4
Atrium I + II
Atrium IV + V
Dr Michael Suppa (DLR)
dbb forum
Partnering
Booths
Morning Coffee
9.00 –9.15
Welcome and Briefing
9.15–11.00
Pitching Spin-Offs
Life Sciences (Focus on MedTech)
Pitching Technologies
ICT (Focus on Big Data)
Partnering
Prescheduled
One-to-OneMeetings
Moderation: Dr Ruth Herzog (DKFZ) / (30 min)
Moderation: Ulrich Mahr / Astrid Giegold (Max Planck Innovation GmbH)
Dr Jörn Krupa (Helmholtz Association)
Discussion
15.45 –16.45 Panel Discussion: Big Data Management and Personalised
Medicine – Future Trends and Challenges
Chairman: Prof. Dr Christof von Kalle (NCT / DKFZ)
Dr Susanne Arbogast (Roche Diagnostics GmbH)
Prof. Dr Khusru Asadullah (Bayer AG)
Manuela Müller-Gerndt (IBM Germany GmbH)
Prof. Dr Hans Lehrach (MPIMG)
Prof. Dr Iris Pigeot (BIPS)
16.45 –18.00 Buletten & Beer
5
Overview dbb forum
Maps of the Venues
Venue of Pitches, Partnering and Conference Sessions
dbb forum Berlin · Friedrichstraße 169 / 170 · 10117 Berlin
Venue of Beckurts Award’s ceremony and evening reception
Berlin Town Hall · Rotes Rathaus · Rathausstraße15 · 10178 Berlin
WC
ATRIUM I + II
Alexanderplatz
^
^
Hauptbahnhof
Friedrichstraße
10
9
20
21
22
23
24
17
18
19
Mohrenstraße
ENTRANCE
Klosterstraße
am
ße
e St r a
Französisch
Französische Straße
REgistration
5
m
Linden
nd
11
Bayer
12
Siemens
13
aße
DBB
Forum
16
5
r den
Unte
hle
Brandenburger Tor
2
Mü
EBD
Bo
sc
h
1
ch
e
2
Ro
s
3
fi
is
15 Spinnovator
4
no
5
Sa
6
IBM
7
Ze
8
Friedrichstr
14 IBB
ße
tra
S
t
ch
Rotes
ne
k
Rathaus
b
e
i
L
rlKa
1
Märkisches Museum
Stadtmitte
1
Spittelmarkt
There are limited parking opportunities. We recommend to travel by public transport.
COFFEE-BAR
6
How to get to the Evening Reception:
5 to 10 min walk to train station Friedrichstraße, then take whether S5, S7 or S75
(going east) to Alexanderplatz or 15 to 20 min walk to Berlin Town Hall
7
PARTNERING
Partnering is the main goal of the Innovation Days. In the run-up to the
event, participants scheduled 30-minute one-to-one meetings via the
well-established online software tool partneringONE®. This platform allows
participants to actively request, confirm or cancel meetings and provides
an optimal meeting schedule to make the best possible use of the time
available on the day. The meetings will be held in separate booths in the
Overview Location.................................................................................page 6
Further Information in the list of participants and in your meeting
schedule (a current version is available at the EBD-Partnering Desk)
dbb forum. The meeting schedule will be created via partneringONE®.
PITCHES
In four sessions on Monday afternoon and Tuesday morning, research
organisations and entrepreneurs from the four research associations will
hold 10‑minute talks presenting up to 40 promising technologies and spinoffs. These pitches will run in parallel in the two fields of Life Sciences
(with a focus on Medical Technologies) and Information and Communication
Overview on Top 40 Pitchings......................................................page 10–13
Detailed Information in the Partnering-System (Pitching Profile)
Technologies (with a focus on Big Data).
CONFERENCE SESSIONS
The conference program starts on 9 December with an impulse talk and
two key notes from outstanding speakers. On 10 December the event
will feature one session on models and best practices for successful
cooperation and one session concerning the opportunities for industry to
use large-scale research infrastructure. An expert discussion will connect
the two foci of the Innovation Days by exploring the promises as well as the
Detailed Information on Conference Sessions...........................page 14–17
challenges of personalised medicine and big data management.
SPONSORS
We would like to thank our co-host Bayer AG and all our partners and
sponsors from society, science, and business for supporting the Innovation
Days 2013 in Berlin. The nine Industry and Venture Capital Sponsors have
Detailed Information on Sponsors.............................................. page 18–27
special fix partnering booths in dbb forum and take part in the Partnering.
8
9
Innovation Days: PITCHINGS LIFE SCIENCES (FOCUS MEDTECH)
TITLE SPEAKER
Organisation
TECHNOLOGIES
Nano meets cells – 3D cell culture the easy way
Dr Petra UhlmannLeibniz Association
ORBIT: fast acquisition of three-dimensional X-ray imaging dataProf. Dr Erwin KeeveFraunhofer
Advanced statistical methods for image & signal processing in medical sciences
Dr Karsten TabelowLeibniz Association
Specific Surface modification of medical implantates by ion implantationProf. Dr Andreas Kolitsch
Helmholtz Association
FLASH II: real-time MRI with hitherto unsurpassed image quality &Prof. Dr Jens FrahmMax Planck Society
spatiotemporal resolution
3D Ultrasound Computer Tomography for early breast cancer detection
Dr Nicole Ruiter
Helmholtz Association
Assisted in vivo fertilizationVeronika MagdanzLeibniz Association
Surface modified closed bag systems for cell generation
Dr Kristina Lachmann˘/Fraunhofer and Dr Henk Garritsen
Helmholtz Association
Silicon Based CMOS Integrated Microfluidic PlatformMehmet KaynakLeibniz Association
LiveCheck: Rapid diagnostic sensor
Dr. Philipp Rittershaus
Helmholtz Association
Invistro GmbH: preclinical synchro- modal diagnostic imaging
Dr Jörg Peter
Helmholtz Association
Droplet-based Microfluidic
Jean-Christophe BaretMax Planck Society
i3 membrane GmbH: porous metallic membrane & corresponding filter modules Dr Stephan Brinke-Seiferth
Spin-Offs
Helmholtz Association
Rapid detection of illicit drugs from human breath using Ion MobilityProf. Dr Oliver KayserLeibniz Association
EmboTX - artificial plugging of tumor supplying blood vessels
Christian ReisFraunhofer
Sciomics: Antibody meets microarray
Dr Christoph Schröder
Helmholtz Association
Ultraviolet Light Emitting Diodes e.g. for disinfection, phototherapy,
Dr Jens RaßLeibniz Association
UV curing, and sensing
Better Hearing
Dominik KaltenbacherFraunhofer
Dualis MedTech GmbH: hydraulic synthetic sphincter withFlorian Frank / Stephan Sagolla
transcutaneous energy supply
LEAP: innovative implantable low-energy defibrilator
10
Helmholtz Association
Dr Stefan LutherMax Planck Society
11
INNOVATION DAYS: PITCHINGS ICT (FOCUS BIG DATA)
TITLE Speaker
Organisation
Dr Heidemarie Schmidt
Helmholtz Association
TECHNOLOGIES
CFlux - building learning computers for big data handling
MOTIF Analysis in NetworksAnatol WegnerMax Planck Society
New method for pseudonymisation and re-identification of patient identifiers
Dr Harald Aamot
Helmholtz Association
Big Language Data
Dr Marc KupietzLeibniz Association
dCache Software for big data
Dr Patrick Fuhrmann
Helmholtz Association
Scent microdosing headset for consumer applicationsMartin RichterFraunhofer
VITAL- Vehicle-Actuated Intelligent Traffic Signal ControlRobert Oertel
Helmholtz Association
Smart Grids / Smart BuildingMathias DalheimerFraunhofer
Self-organizing network synchromization
Dr Johannes KlinglmayrMax Planck Society
High-performance computing platform based on MTCA.4 standard
Dr Thomas Walter
Helmholtz Association
Spin-Offs
emMotRac: movement compensation in real-time in MRI
Dr Jessica SchulzMax Planck Society
Clueda AG - Beyond Big Data: intelligent semantic software solutions Dr Volker Stümpflen
Helmholtz Association
Alacris - predicting the effect of drug treatmentPD Dr Bodo LangeMax Planck Society
Kastanienbaum GmbH: Safety and distributed Programming for Soft-Robots
Dr Sami Haddadin
Helmholtz Association
THE CAPTURY: A new motion capture paradigm
Dr Nils HaslerMax Planck Society
High Definition Stereoscopic 3D Live Streaming
Dr Marcel Kunze
Helmholtz Association
PROXIMITY – A revolution in game audioOlaf StepputatFraunhofer
Aircloak: A new technology for anonymizing dataFelix BauerMax Planck Society
Songpier Cross-Screen ServiceMatthias GlatschkeFraunhofer
Artistic Freedom for Realistic Computer GraphicsThorsten Schmidt / Anton Kaplanyan 12
Helmholtz Association
13
Opening Plenary Session
dbb forum Atrium (I+II)
9 DECEMBER 2013 | 13.30 – 15.00
Session I
dbb forum Atrium (I+II)
10 DECEMBER 2013 | 11.15 – 13.00
Welcome and Introduction
Models, Deals and Instruments
Dr Rolf Zettl (Managing Director, Helmholtz Association),
Chairman of the Session
Chairman: Dr Jörn Erselius (CEO, Max Planck Innovation GmbH)
Impulse Talk on Innovation by Partnering and Cooperation
Prof. Dr Wolfgang Plischke (Board of Management, Bayer AG)
Key Note on Research and Innovation in Medical Technologies / Big Data
From scanning tunneling microscope to Tissue Phenomics and Big Data
Prof. Dr Gerd Binnig (Definiens AG), Nobel Prize in Physics 1986
Key Note on Research and Innovation in ICT / Big Data
How to be a Game Changer: Innovations in Audio
Prof. Dr Karlheinz Brandenburg (Fraunhofer Institute for Digital Media
Technology IDMT), co-inventor of the MP3 format
Rotes Rathaus
9 DECEMBER 2013 | 17.45 –19.15
Key Note at Beckurts Awards Ceremony (in German)
Prof. Dr Harald zur Hausen (German Cancer Research Center, DKFZ),
Nobel Prize in Physiology or Medicine 2008
Success factors in the strategic partnership between Bayer and DKFZ
Dr Ruth Wellenreuther (German Cancer Research Center, DKFZ) and
Dr Holger Hess-Stumpp (Director Strategic Alliance Management
Oncology / Gynecological Therapy, Bayer Pharma AG)
Fraunhofer Industry Collaborations: How does it work?
Prof. Dr Ralf Dudde (Fraunhofer Institute for Silicon Technology, ISIT / Mems
Foundry Itzehoe GmbH)
Lead Discovery Center (LDC): A New Model for Pharma Innovation
Dr Bert Klebl (CEO, Lead Discovery Center GmbH, LDC) and Julie Wallis
(Head of Partnership Management Global Licensing & Business Development, Merck Serono)
Financing Innovation: From Spinnovator to HTGF and Venture Capital
Dr Katja Rosenkranz (Senior Project Manager Spinnovator / Ascenion
GmbH), Matthias Dill (Investment Manager, High-Tech Gründerfonds Management GmbH, HTGF) and Ute Mercker (Senior Investment Managerin, IBB
Beteiligungsgesellschaft mbH)
Discussion
Welcome
Cornelia Yzer (Senator for Economics, Technology and Research)
Prof. Dr Jürgen Mlynek (President Helmholtz Association)
Prof. Dr Wolfgang Plischke (Board of Management, Bayer AG)
Rotes Rathaus | Evening Reception
9 DECEMBER 2013 | 19.15 – 22.00
14
15
Session II
dbb forum Atrium (I+II)
10 DECEMBER 2013 | 14.00 – 15.45
Session III
dbb forum Atrium (I+II)
10 DECEMBER 2013 | 15.45 – 16.45
Using unique Infrastructure
Panel Discussion
Chairman: Prof. Dr Andreas Schreyer (Director German Engineering Materials Science Centre [GEMS], Institute of Materials Research, Helmholtz
Center Geesthacht, HZG)
Big Data Management and Personalised Medicine – Future Trends and
Challenges
Introduction and Overview of large-scale research facilities with a focus on
PETRA III, XFEL, BERII, BESSY II, ANKA, Ion Beam Center
Prof. Dr Kaysser-Pyzalla (Scientific Director, Helmholtz-Zentrum Berlin for
Material and Energy, HZB)
How can industry take advantage of large-scale research facilities? The
case of drug discovery
Dr Martina Schäfer (Structural Biology, Bayer Pharma AG)
Material Testing and Research with Synchrotrons and Neutrons
Dr Thomas Gutberlet (Head of User Coordination, Helmholtz-Zentrum Berlin
for Material and Energy, HZB) and Dr Hermann Franz (Deutsches Elektronen-Synchrotron DESY)
Leibniz Application Labs
Dr Silvia Adelhelm (Leibniz Institute for Astrophysics Potsdam, AIP)
Chairman: Prof. Dr Christof von Kalle (National Center for Tumor Diseases,
NCT / German Cancer Research Center, DKFZ)
Dr Susanne Arbogast (Head Innovation Network & External Affairs, Roche
Diagnostics GmbH)
Prof. Dr Khusru Asadullah (Vice President, Head of Global Biomarker, Bayer
Pharma AG)
Manuela Müller-Gerndt (Healthcare & Pharma / Life Sciences,
IBM Germany GmbH)
Prof. Dr Hans Lehrach (Director, Max Planck Institute for Molecular
Genetics)
Prof. Dr Iris Pigeot (Director, Leibniz Institute for Prevention Research and
Epidemiology)
Fraunhofer Application Center for Plasma and Photonics APP and
HAWK Goettingen
Dr Bernd Schieche (Innovation Manager, Fraunhofer Institute for Surface
Engineering and Thin Films IST)
Medical Innovation Lab
Dr Michael Suppa (Head of Department in the Institute of Robotics and
Mechatronics, German Aerospace Center, DLR)
Discussion
16
17
Bayer: Science For A Better Life
Bayer is a global enterprise with core competencies in the fields of health care, nutrition and
high-tech materials. The company’s products and services are designed to benefit people
and improve their quality of life. At the same time Bayer creates value through innovation,
growth and high earning power. The Group is committed to the principles of sustainable
development and to its role as a socially and ethically responsible corporate citizen. Economy,
ecology and social responsibility are corporate policy objectives of equal rank.
Bayer is an inventor company with a long tradition of research. By applying science to the
major global challenges, we deliver innovations that address unmet customer and market
needs. Our focus on innovation is the key to maintaining or gaining a leading position in every
market in which we operate. It is also the foundation for improving the lives of many millions
of people: We help patients around the world by preventing, alleviating and curing diseases
as well as improving diagnosis. We ensure a sufficient supply of high-quality food, feed and
fiber. We make significant contributions in the fields of
energy and resource efficiency, mobility and home living –
to name just a few.
We work sustainably and accept our role as a socially and
ethically responsible corporate citizen. Science For A Better
Life: this is the promise we all give to our stakeholders.
18
19
Platin Sponsor
Gold Sponsor
About SIEMENS
About Roche
Innovations have been one of the key pillars of Siemens’ success for more
Headquartered in Basel, Switzerland, Roche is a leader in research-focused
than 165 years. Our innovations are produced by around 30,000 resear-
healthcare with combined strengths in pharmaceuticals and diagnostics.
chers and developers who are working on new technologies for the areas of
Roche is the world’s largest biotech company, with novel and truly differen-
energy, infrastructure, industry and healthcare – and via the about 1,000 new
tiated medicines in oncology, infectious diseases, inflammation, metabolism
research partnerships which Siemens participates in every year with partners
and neuroscience. Roche is also the world leader in in vitro diagnostics and
around the world. Around 17,000 of our employees in research and develop-
tissue-based cancer diagnostics, and a frontrunner in diabetes management.
ment are software engineers, making Siemens one of the largest software
Roche’s personalised healthcare strategy aims at providing medicines and di-
companies in the world. In fiscal 2013, Siemens invested some R4,3 billion
agnostic tools that enable tangible improvements in the health, quality of life
in research and development. Siemens have been granted some 60,000
and survival of patients. In 2012 Roche had over 82,000 employees worldwide.
patents worldwide. In patent applications, we were No. 3 in Germany and No.
As a research-focused company over 8 billion Swiss francs were invested in
2 in Europe in 2012 – again making us the leading applicant among European
R&D to exploit the latest discoveries and technologies to develop medically
companies. In the U.S., we were No. 11 in patents granted. In fiscal 2013,
differentiated products. The Group posted sales of 45.5 billion Swiss francs.
Siemens employees submitted around 8,400 invention disclosures – an ave-
Genentech, in the United States, is a wholly owned member of the Roche
rage of about 38 per workday. Around 40 percent of the company’s R75,9
Group. Roche is the majority shareholder in Chugai Pharmaceutical, Japan.
billion revenue (fiscal 2013) is generated by green products and solutions.
In Germany, Roche employs over 14,000 people on the three major sites
Among the latest innovations of Siemens are in the field of power generation,
Mannheim, Grenzach and Penzberg. More than 5,000 employees work at the
our direct-drive wind turbines, which are lighter and have fewer components
Biotech-Center in Penzberg, a Power-House for innovative antibody design
than conventional systems, generating renewable energy even more reliably
with focus on oncology projects. For more information, please visit www.
than before. In the area of transportation, our trains, metros and light-rail
roche.com.
vehicles are providing safe, ecofriendly transport for commuters and other
travelers worldwide. In the industry segment, our product lifecycle management (PLM) software is enabling engineers to develop, simulate, test and
reproduce entire production processes in a virtual environment – before a
single screw is manufactured. In the healthcare field, our innovative 64-slice
SOMATOM Perspective computed tomography (CT) scanner is reducing
patient radiation doses by as much as 60% – thanks to our SAFIRE method,
which also improves image quality by reconstructing CT images on the basis
of raw data. For more information, please visit www.siemens.com.
20
21
Silver Sponsor
Sanofi-Aventis Deutschland GmbH
A member of the Sanofi Group
Sanofi is one of the world‘s leading healthcare companies. More than
110,000 employees work in the service of health in approx. 100 countries
worldwide. They research, develop and market therapeutic solutions with
the aim of improving the lives of humans. Germany is one of the company’s
key sites after the USA and its home market France. Of the ten largest
pharmaceutical companies in the world (in terms of market value), Sanofi
is the only company in Germany which covers the whole value chain of the
pharmaceutical business and is engaged in both significant research and
production at its German site.
Innovation plays a key role in Sanofi’s corporate strategy and especially at
its research-oriented local company in Germany. Sanofi has repositioned its
22
The Bosch Group is a leading global supplier
of technology and services. In fiscal 2012, its
roughly 306,000 associates generated sales of
52.5 billion euros. Since the beginning of 2013,
its operations have been divided into four business sectors: Automotive Technology, Industrial
Technology, Consumer Goods, and Energy and
Building Technology. The Bosch Group comprises Robert Bosch GmbH and its roughly 360
subsidiaries and regional companies in some 50
countries. If its sales and service partners are
included, then Bosch is represented in roughly
150 countries. This worldwide development, manufacturing, and sales network is the foundation
for further growth. Bosch spent some 4.8 billion
euros for research and development in 2012, and
applied for nearly 4,800 patents worldwide. The
Bosch Group’s products and services are designed to fascinate, and to improve the quality of life
by providing solutions which are both innovative
and beneficial. In this way, the company offers
technology worldwide that is “Invented for life.”
The company was set up in Stuttgart in 1886
by Robert Bosch (1861–1942) as “Workshop for
Precision Mechanics and Electrical Engineering.”
The special ownership structure of Robert Bosch
GmbH guarantees the entrepreneurial freedom of
the Bosch Group, making it possible for the company to plan over the long term and to undertake
significant up-front investments in the safeguarding of its future. Ninety-two percent of the share
capital of Robert Bosch GmbH is held by Robert
Bosch Stiftung GmbH, a charitable foundation. The
majority of voting rights are held by Robert Bosch
Industrietreuhand KG, an industrial trust. The entrepreneurial ownership functions are carried out
by the trust. The remaining shares are held by the
Bosch family and by Robert Bosch GmbH.
Additional information is available online at
www.bosch.com, www.bosch-press.com and
http://twitter.com/BoschPresse
research and development as part of a global adjustment process, creating
a completely new organization to enable the company to tackle the challenges ahead successfully.
In line with the rapid pace of developments in the scientific environment,
especially in biopharmaceutical research and biology, the research and
development organization is oriented towards maximum flexibility and
openness for external collaboration. The goal is a quick time-to-market for
innovative therapeutics. That also requires cooperation between research,
production and marketing in integrated business units whose every action
is guided by the interests of patients and customers, such as doctors,
health insurance companies and hospitals. To the same degree, however,
scientists should expressly collaborate with external partners, preferably
the world’s best-in-class providers.
23
Silver Sponsor
IBM is a global technology and innovation company that stands for progress
and operations in over 170 countries worldwide. Healthcare is one of IBM’s
focus strategic industry segments and the company is responding rapidly
with innovative solutions for Healthcare sector requirements around the
world. IBM invests approximately $6 Billion annually in research and development. The IBM Research Division has worldwide 12 research laboratories
and a global community of over 3,000 forward-thinkers working towards a
common goal: progress. Patenting is an important barometer of that innova-
Carl Zeiss AG
The ZEISS Group is an international leader in the fields
of optics and optoelectronics. In fiscal year 2011/2012,
the company’s approx. 24,000 employees generated
revenue of 4.163 billion euros.
As the pioneer of science in optics, ZEISS continues
to challenge the limits of man‘s imagination. With
our passion for excellence, we create value for our
customers and inspire the world to see in new ways.
Since its foundation, the company has been shaped
by outstanding researchers and innovators. Founders
Carl Zeiss and Ernst Abbe, together with Otto Schott,
established the modern optical industry and enabled
fundamental discoveries in medicine and science. The
company still continues this tradition to this very day.
tion, and IBM has topped in 2012 the annual list of U.S. patent recipients for
Approximately 10 percent of the global workforce
is employed in research and development. Highlyqualified physicists, scientists and engineers
with specialist knowledge in optics and precision
mechanics develop new products and innovations,
thus allowing ZEISS to tap into new business sectors.
To further expand the company‘s leading position
in a wide variety of technologies, the ZEISS Group
invests in research and development on an ongoing
basis: in fiscal year 2011/12 ZEISS used nine percent
of revenue – the equivalent of 390 million euros
(prior year: 359 million euros) – for this purpose.
the 20th consecutive year. These innovations show IBM’s long-term, strategic
commitment to innovation and demonstrate the patience to allow scientific
discovery to find its way into the market. IBM Research has had five Nobel
Prize laureates in its community, including Gerd Binnig and Heinrich Rohrer
for the invention of the scanning tunneling microscope – which started
the modern era of nanotechnology. For Healthcare, IBM’s overall goal is to
support the transformation of the healthcare industry to achieve the goals
of patient-centered, personalized health management that is safer, more
efficient and provides better outcomes. IBM invented “Watson”, a computing
system that rivals a human‘s ability to answer questions fast and accurate
and can suggest options and assist decision makers in identifying diagnosis and treatment options. IBM cooperates with Memorial Sloan Kettering
The company has stood for innovation for more
than 160 years. The research and development
teams work intensively on constantly expanding
the technology leadership. The ownership structure
lays the foundation for ensuring that investments in
innovations can be made with vision and foresight.
Cancer Center to develop a tool built upon Watson in order to ease access
to latest cancer practices and to help doctors to create individualized cancer
diagnostic and treatment recommendations. The IBM Academic Initiative, a
program for college and university professors, is providing training materials,
curriculum guides, software and hardware needed to teach in-demand business and technology skills. Furthermore, the IBM University Awards support
basic research, curriculum innovation, and educational assistance in focus
areas that are fundamental to innovation in the 21st Century and strategic to
IBM‘s core business, such as healthcare.
24
25
Supporting Venture Capital Partners
About IBB Beteiligungsgesellschaft mbH
The IBB Beteiligungsgesellschaft provides venture capital to innovative Berlin enterprises and has established itself as a market leader in the field of
early stage financing in the location Berlin. The funds are used primarily for
the development and market launch of innovative products or services. The
funds are financed by means of the Investitionsbank Berlin (IBB) and the
European Fund for Regional Development (EFRE) administered by the State
Berlin. Since 1997 the IBB Beteiligungsgesellschaft in consortia with partners, has made 850 million R available to technology-oriented companies;
thereof, the portion invested by IBB Beteiligungsgesellschaft itself was approximately 116 million R. In 2013 the IBB Beteiligungsgesellschaft closed
financing rounds with three new Life Science enterprises: Myelo Therapeutics, machtfit and Scopis. New investments in the Information and Communication Technologies (ICT) field are Meetrics, SuitePad and labfolder.
SPINNOVATOR
LIFE SCIENCE VENTURE CAPITAL
The Spinnovator is an innovative technology transfer
instrument for research and transfer institutes supported
by the BMBF. We combine government funding with venture capital and
professional expertise to develop particularly promising publicly funded
research projects into marketable applications. This process always involves
the establishment of a spin-off company. Each spin-off may receive funding
of up to EUR 3.7 million from the BMBF that must be matched by venture
capital to at least an equivalent sum. The Spinnovator is managed by a team
of experienced Ascenion staff. We coordinate cooperation between our various partners – the BMBF, research institutes, scientists, technology transfer
organizations and venture capitalists – and carry out the due diligence, selection and development of potential projects. The decision regarding financing
is made together with our venture capital partners and in consultation with
the BMBF. Find further information at www.spinnovator.de.
26
27
With generous Support of
Stifterverband für die
Deutsche Wissenschaft
BDI
Stifterverband is the business community‘s innovation agency for the
The Federation of German Industries (BDI) – the Voice of German Industry –
German science system. It is a private, dedicated and not-for-profit asso-
communicates the interests of German industry to those in positions of poli-
ciation. Through donations, membership fees and other forms of income,
tical responsibility. It primarily addresses policy-makers and the government
Stifterverband generates annual funds of well over 160 billion EUR, making
in Germany and at EU level. In addition, the BDI is also active worldwide. It
it the largest private institution of its kind in Germany. Stifterverband‘s work
commands a wide network in all key markets and international organizations.
centres on creating a productive and open knowledge society. Its goal is
The BDI provides political flanking for the opening up of international markets
to work together effectively with universities, institutes and companies, al-
and provides information and economic policy advice on all topics relevant to
lowing homegrown talent to be developed to its full potential and new ideas
industry. The BDI is an association of associations. Currently, it has 38 Mem-
to be brought to fruition. Stifterverband is a major driving force behind the
ber federations, of which 2 are working groups, and represents the interests
cooperation between industry and science and behind the dialogue between
of 100.000 businesses with 8 million employees. Membership is voluntary.
academia and the general public. Tens of millions of euros are invested by
Stifterverband in programmes, prizes and initiatives designed to boost autonomy and competition in Germany‘s academic system.
BERLIN PARTNER
Berlin Partner for Business and Technology provides business and technology
support to companies, investors and scientific institutions in Berlin. With
customized services and an excellent scientific network at their fingertips,
the many specialists here create optimal programs to guide innovation, relocation, expansion, and location development projects in Berlin to success.
For example, Berlin Partner for Business and Technology is responsible for
managing the Healthcare Industries Cluster, one of the leading life sciences
centers in the world, in cooperation with ZAB ZukunftsAgentur Brandenburg.
As a unique public-private partnership, the Senate of the State of Berlin and
over 200 companies share their passion for Berlin with Berlin Partner for
Business and Technology. Berlin Partner is also responsible for marketing the
German capital to the world, with campaigns such as the highly visible “be
Berlin” campaign.
28
29
Research Organizations
HELMHOLTZ ASSOCIATION
FRAUNHOFER
The Helmholtz Association is dedicated to pursuing the long-term research
The Fraunhofer-Gesellschaft is the leading organization for applied research
goals of state and society, and to maintaining and improving the livelihoods
in Europe. Its research activities are conducted by 66 Fraunhofer Institu-
of the population. In order to do this, the Helmholtz Association carries
tes at over 40 different locations throughout Germany. The Fraunhofer-
out top-level research to identify and explore the major challenges facing
Gesellschaft employs a staff of around 22,000 who work with an annual
society, science and the economy. Its work is divided into six strategic
research budget totaling 1.9 billion euros. Roughly two thirds of this sum
research fields: Energy; Earth and Environment; Health; Key Technologies;
is generated through contract research on behalf of industry and publicly
Structure of Matter; and Aeronautics, Space and Transport. Along the lines
funded research projects. Branches in the USA and Asia serve to promote
of use inspired research we are committed to carrying out ambitious basic
international cooperation. Founded in 1949, the research organization takes
research geared towards practical applications in the real world. The trans-
its name from Joseph von Fraunhofer (1787–1826), the illustrious Munich
fer of knowledge and technology plays a decisive role in achieving this. It
researcher, inventor and entrepreneur.
ensures that research findings flow directly into society and policymaking
processes or are channeled into commercial innovations.
Max Planck Society
LEIBNIZ ASSOCIATION
The Max Planck Society is one of the most successful research organi-
The Leibniz Association is made up of 86 independent research institutes,
zations worldwide. The currently 80 Max Planck Institutes conduct basic
which conduct problem-oriented research and provide scientific infra-struc-
research in the service of the general public in the natural sciences, life
tures of national and international significance. They work in fields such as
sciences, social sciences, and the humanities. Max Planck Institutes focus
mathematics, optical technologies, materials research, bio-medical research,
on research fields that are particularly innovative, or that are especially
environmental research, bio- and nanotechnology, as well as biodiversity,
demanding in terms of funding or time requirements. And their research
economic policy, and educational research. Within a total budget of 1.4 billion
spectrum is continually evolving. This continuous renewal preserves the
euro, about E330 million come from third-party funds. Leibniz Institutes
scope the Max Planck Society needs to react quickly to pioneering scien-
currently coordinate 75 projects funded by the European Union.
tific developments. At the Max Planck Society, Max Planck Innovation is
responsible for technology transfer.
30
31
Spark your own ideas…
32
33
Spark your own ideas…
See you in 2014!
The next Innovation Days will take place in Munich.
Save the Date: 01. / 02.12.2014 (HVB Forum)
Detailed Information about today’s workshops and presentations:
www.helmholtz.de / innovationdays / presentations
Login: to do
For further Information:
Dr Ing. Jörn Krupa
Helmholtz Association of German Research Centres
Head Office Technology Transfer
Anna-Louisa-Karsch-Straße 2
10178 Berlin
Tel.:+49 30 206 329-72
Fax:+49 30 206 329-70
Publisher
Hermann von Helmholtz Association of German Research Centres
Responsible for content
Communications and Media Relations, Helmholtz Head Office
Satz
WIENBERLIN – Gregor Hüttner, Berlin
Printer
Druckerei J. Humburg GmbH, Berlin
Picture
© www.dreamstime.com
As of
November 2013
Registered office of the Helmholtz Association
Ahrstraße 45, D-53175 Bonn
Telephone: +49 (0) 228 30 818-0, Telefax: +49 (0) 228 30 818-30
E-Mail: info@helmholtz.de
www.helmholtz.de
34
35
We would like to thank our sponsors from industry
and our supporting Venture Capital Partners for their
involvement in this inspiring event.
Co-Host
Platin Sponsors
Gold Sponsors
Silver Sponsors
Venture Capital Partners
Supporting Venture Capital Partners
LIFE SCIENCE VENTURE CAPITAL
With Generous Support of
Organisation of partnering supported by